Clinical Trials Directory

Trials / Completed

CompletedNCT04123288

A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men

Single-center, Open-label, Randomized, Two-way Crossover Study to Compare the Single-dose Pharmacokinetics of Pediatric Minitablet and Adult Capsule Formulations of ACT-709478 in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Idorsia Pharmaceuticals Ltd. · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study is for research purposes only and is not intended to treat any medical condition. The purpose of this study is to evaluate the pharmacokinetics of 2 different formulations of ACT-709478 in healthy male participants. The participants will be treated in a crossover design with 2 different treatment periods. Pharmacokinetics (PK) is the study of the absorption and breakdown of the study drug in the body. The duration of participation in this study is approximately 8 weeks from screening to the end of study visit. A screening visit is required within 21 to 3 days prior to the start of the study to determine whether the participant qualifies and is willing to enter in this research study. This study requires the participant to have two in-patient stays in the research clinic. Each in-patient stay is planned for 5 days (4 nights). Eleven days after each dose the participant will have an examination. There will be an in-between period (i.e., time between the end of period 1 and study treatment administration in Period 2) of 7 to 14 days. A safety follow-up telephone call for all participants who have received at least one study treatment will take place 30 to 40 days after the end of study examination or study discontinuation.

Conditions

Interventions

TypeNameDescription
DRUGACT-7094781 film-coated minitablet contains 2 mg of ACT-709478
DRUGACT-7094781 hard capsule contains 10 mg of ACT-709478.

Timeline

Start date
2019-12-16
Primary completion
2020-02-05
Completion
2020-02-05
First posted
2019-10-10
Last updated
2020-02-25

Locations

1 site across 1 country: Czechia

Source: ClinicalTrials.gov record NCT04123288. Inclusion in this directory is not an endorsement.